QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2028

Conditions

Bone and Soft Tissue Tumors

Interventions

DRUG

QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

5mg/kg iv q3w

Trial Locations (1)

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER

NCT06939855 - QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter